Huge British coronavirus drug trial could produce results by June


Britain has enrolled more than 5,000 COVID-19 patients, or 10 percent of the country's cases, in a clinical trial to test out several drugs to treat the new coronavirus. The Recovery trial, conducted at 165 National Health Service hospitals, is "by far the largest trial in the world," Peter Horby, the Oxford University infectious disease professor leading it, told The Guardian. With such a large number of subjects, "we're guessing some time in June we may get the results," though "if it is really clear that there are benefits, an answer will be available quicker," he added.
The study has randomly split the subjects into groups of 500 to 900 to test different drugs, with 2,000 patients getting placebos in a control group. Among the drugs being tested — first individually, but later perhaps in different combinations — are the anti-malaria drug hydroxychloroquine, the antibiotic azithromycin, two HIV antiretroviral drugs (lopinavir-ritonavir), and the anti-inflammatory steroid dexamethasone. Horby said his team will include other drugs soon and hopes to obtain a supply of the experimental antiviral drug remdesivir.
"We haven't got anything like a magic bullet," Horby cautioned. "I think we have to temper people's expectations about these drugs. It's possible some might have an effect, but it's likely to be modest. I think what we'll be looking at in terms of making a significant impact will be moving on to combinations once we know of things that work." Read more about the Recovery trial at The Guardian.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
FIRE is catching as people want to leave the traditional workforce
In the spotlight Many are taking steps to retire early
-
How might Bari Weiss change CBS News?
Talking Points Is the network trying to ‘appease’ the president?
-
‘A legacy news brand brings a visibility of its own’
Instant Opinion Opinion, comment and editorials of the day
-
Gold tops $4K per ounce, signaling financial unease
Speed Read Investors are worried about President Donald Trump’s trade war
-
Electronic Arts to go private in record $55B deal
speed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance